← Back

Wire · opportunities

Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in ...

Published

11 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at prnewswire.com →

◆ Verified

Fusion42 · 11 November 2026 · Fusion42 review

Ascletis has submitted an Investigational New Drug (IND) application to the U.S. FDA for ASC30_39 FDC, a novel oral fixed-dose combination therapy targeting obesity by combining a GLP-1 receptor agonist and a selective amylin receptor agonist.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 11 Nov 2026 and 17 Nov 2026.

◆ ◆ The Wire takeaway

Your obesity drug startup faces a higher bar as first-in-class oral therapies attract regulatory focus. Clarify FDA engagement paths now to speed clinical plans and seize market lead.

◆ Coverage

2 sources · first reported 11 Nov 2026 · latest 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfdaind-applicationobesity-treatmentoral-drugdrug-development